Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic viable Wharton's jelly-derived mesenchymal stem cells
- Development stage
- Unknown
- Lead developer
- Fundació Institut Guttmann
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intrathecal
01
Overview
Allogeneic viable Wharton's jelly-derived mesenchymal stem cells are an **off-the-shelf mesenchymal stromal cell therapy** prepared from the Wharton's jelly of donated human umbilical cords for regenerative medicine applications, including development by **Fundacio Institut Guttmann** for **traumatic spinal cord injury**. The product is intended to be administered **intrathecally** in SCI programs and is being explored for its ability to modulate the post-injury inflammatory milieu, secrete trophic and reparative factors, support neuronal and glial survival, and promote tissue sparing and functional recovery rather than acting through a single ligand-receptor target. In the Guttmann program, Wharton's jelly MSCs have been supported by preclinical spinal cord injury work and are being clinically investigated in chronic traumatic SCI, including a pilot study combining intrathecal WJ-MSC administration with transcutaneous spinal cord stimulation.
- Other names
- Wharton's jelly mesenchymal stem cellsWJ-MSCsMSC,WJumbilical cord-derived mesenchymal stem cells
Beyond the preview
Go deeper on allogeneic viable Wharton's jelly-derived mesenchymal stem cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic viable Wharton's jelly-derived mesenchymal stem cells.